Citadel Advisors’s Organogenesis Holdings ORGO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.29M Sell
544,235
-24,931
-4% -$86.4K ﹤0.01% 7090
2025
Q4
$2.95M Buy
+569,166
New +$2.76M ﹤0.01% 5196
2025
Q3
Sell
-100,779
Closed -$468K 13731
2025
Q2
$369K Sell
100,779
-135,951
-57% -$507K ﹤0.01% 9336
2025
Q1
$1.02M Sell
236,730
-19,071
-7% -$77K ﹤0.01% 6907
2024
Q4
$819K Buy
255,801
+117,947
+86% +$396K ﹤0.01% 7462
2024
Q3
$394K Sell
137,854
-46,363
-25% -$130K ﹤0.01% 8752
2024
Q2
$516K Sell
184,217
-43,714
-19% -$117K ﹤0.01% 7976
2024
Q1
$647K Sell
227,931
-230,861
-50% -$785K ﹤0.01% 7815
2023
Q4
$1.88M Sell
458,792
-159,982
-26% -$448K ﹤0.01% 5474
2023
Q3
$1.97M Sell
618,774
-1,242,416
-67% -$3.95M ﹤0.01% 5244
2023
Q2
$6.18M Sell
1,861,190
-690,700
-27% -$2.04M ﹤0.01% 3319
2023
Q1
$5.44M Buy
2,551,890
+1,876,307
+278% +$4.64M ﹤0.01% 3671
2022
Q4
$1.82M Sell
675,583
-451,546
-40% -$1.32M ﹤0.01% 5653
2022
Q3
$3.65M Buy
1,127,129
+383,714
+52% +$1.73M ﹤0.01% 4422
2022
Q2
$3.63M Sell
743,415
-43,881
-6% -$270K ﹤0.01% 4409
2022
Q1
$6M Buy
787,296
+580,717
+281% +$4.49M ﹤0.01% 3827
2021
Q4
$1.91M Sell
206,579
-225,522
-52% -$2.4M ﹤0.01% 6355
2021
Q3
$6.15M Sell
432,101
-158,456
-27% -$2.46M ﹤0.01% 3926
2021
Q2
$9.81M Buy
590,557
+78,946
+15% +$1.47M ﹤0.01% 3110
2021
Q1
$9.32M Buy
511,611
+385,068
+304% +$5.22M ﹤0.01% 3075
2020
Q4
$953K Buy
+126,543
New +$601K ﹤0.01% 6899
2020
Q2
Sell
-23,715
Closed -$77K 10301
2020
Q1
$77K Sell
23,715
-39,213
-62% -$168K ﹤0.01% 8808
2019
Q4
$303K Buy
62,928
+43,247
+220% +$274K ﹤0.01% 7570
2019
Q3
$129K Sell
19,681
-6,631
-25% -$36.9K ﹤0.01% 8365
2019
Q2
$200K Buy
+26,312
New +$193K ﹤0.01% 8189

Other funds holding ORGO

Citadel Advisors's ORGO Position: Q1 2026 in Review

Citadel Advisors reduced its Organogenesis Holdings (ORGO) stake by 4.4% in Q1 2026, selling an estimated $86.4K and leaving 544,235 shares worth $1.29M. The position accounts for ﹤0.01% of the portfolio, ranked #7090.

Citadel Advisors first reported a position in ORGO in Q2 2019 and has held it in 25 quarters since. The position peaked at $9.81M in Q2 2021. 121 funds tracked by Wall St. Rank hold ORGO as of Q1 2026.

  • Citadel Advisors held 544,235 shares of Organogenesis Holdings worth $1.29M as of Q1 2026.
  • Citadel Advisors sold 24,931 Organogenesis Holdings shares in Q1 2026, an estimated $86.4K.
  • Organogenesis Holdings made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #7090 holding.
  • Citadel Advisors first reported a position in Organogenesis Holdings in Q2 2019 and has held it in 25 quarters since.
  • Citadel Advisors's Organogenesis Holdings position peaked at $9.81M in Q2 2021.
  • 121 funds tracked by Wall St. Rank held Organogenesis Holdings as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.